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Background: Intradermal tests (IDTs) are performed and interpreted differently in drug
allergy centers making valid comparison of results difficult.
Objective: To reduce method-related and intercenter variability of IDTs by the
introduction of a standardized method.
Materials and methods: In 11 centers of the European Network for Drug Allergy, IDTs
were prospectively performed with saline and with amoxicillin (20 mg/ml) using (1) the
local method and (2) the standardized European Network in Drug Allergy (ENDA) method
(0.02ml). The diameters of the initial injection wheal (Wi) for the different volumes and sites
injected obtained from each center were analyzed.
Results: Themost reproducible method was to fill a syringe with test solution, then expel
the excess fluid to obtain exactly 0.02ml. The median Wi diameter with 0.02ml injection
using the standardized method was 5mm [range 2–10mm; interquartile range (IQR)
5–5mm; n = 1,096] for saline and 5mm (range 2–9mm; IQR = 4.5–5mm; n = 240) for
amoxicillin. IDT injection sites did not affect the Wi diameter. Training improved precision
and reduced the variability of Wi diameters.
Conclusion: Using the standardized IDT method described in this multicenter study
helped to reduce variability, enabling more reliable comparison of results between
individuals and centers.
Keywords: drug allergy, intradermal test, amoxicillin, standardization, specificity of drug skin tests
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INTRODUCTION
Allergy skin testing is essential for the correct diagnosis of
immediate and delayed drug hypersensitivity (DH). It is also
used to identify alternative drugs for patients with positive skin
or provocation tests with suspected drugs. The intradermal test
(IDT) is the most sensitive skin test and may be used when
soluble forms of the drugs are available. A questionnaire survey in
2004 (1) within the European Network in Drug Allergy (ENDA),
the Drug Allergy Interest Group of the European Academy of
Allergy and Clinical Immunology (EAACI), showed differences
in performing drug allergy investigations. Guidelines such as
those by the European Society of Contact Dermatitis (ESCD)
(2), the EAACI (3), anesthesiology societies (4, 5), and the
United States of America (6) differ in their recommendations
(Table 1), making valid comparison of the results between centers
virtually impossible. A position paper providing guidelines on
drug concentrations for skin testing was published in 2013 (7),
but at the present time, there is no consensus on themethodology
and interpretation of drug IDT. The drug concentration, the
method used, and the criteria for positive skin tests all influence
the sensitivity and specificity of IDT; consequently, thresholds
for specific results may vary between different centers (8, 9).
Barbaud et al. (8), using the ESCD guideline, showed that
the highest specific concentration before causing an irritant
reaction for cefotiam was 10 mg/ml and, for cefotaxime, 25
mg/ml, but Torres et al. (9) in the EAACI Interest Group
on DH position paper recommended using 1–2 mg/ml for
cephalosporin IDT.
A questionnaire survey on the skin test methods used by
different centers in the ENDA group was carried in 2008/2009.
TABLE 1 | Comparison of international guidelines published for performing drug intradermal tests.
ESCD (2) EAACI (3) BSACI (4) SFAR (5) Macy et al. (6)
Volume injected 0.04ml sequential dilutions
in saline or phenolated
saline
0.02–0.05ml 0.03ml 0.02–0.05ml 0.02ml with a
27-gauge tuberculin
Measurement of the Wi Yes
Raising a wheal of 4–6 mm
Yes
Raising a bleb of 3mm
Yes





Time interval to immediate
skin test reading (minutes)
30 15–20 20–30 20 15
Criteria for immediate
positivity
Wheal ≥10mm W20 ≥ Wi+ 3mm with
surrounding flare
A wheal that is ≥3mm
larger than the initial
bleb with surrounding
flare
W20 ≥ Wi × 2 Wheal ≥5mm with a
surrounding erythema
Criteria for delayed positivity Papule at 24 h 24–72 h
infiltrated
erythema
Not defined Not defined Not defined
Site Extensor surface of the arm Volar aspect of the forearm
(or other regions)
Not defined Back, arm or forearm Not specified
Negative control with saline Yes Yes Yes Yes Yes, with Tris-buffered
saline
ESCD, European Society of Contact Dermatitis; EAACI, European Academy of Allergy and Clinical Immunology; BSACI, British Society for Allergy and Clinical Immunology, Societe
Francaise d’Anesthesie et Reanimation.
Wi, diameter of initial wheal just after injection; W20, diameter of the wheal 20-min post-injection.
It showed a wide variation in the method used and in the
interpretation of the results. This led to the setting up of
a multicenter study comparing local IDT methods with the
proposed new standardized IDT method based on the ENDA
consensus and to determine if the standardized method will
minimize the intercenter variability in performing IDT. As
the initial results and analysis had showed large variation in
the diameter of initial wheal just after injection (Wi) readings
obtained in the different centers, a practical session was organized
during an ENDAmeeting in one participating hospital.We noted
the different ways of filling the syringe and differences in the
injection needle gauge, injection, and test measurement methods.
A standardized IDT (the Guideline) was written and validated by
all coauthors.
MATERIALS AND METHODS
All tests performed in this prospective descriptive study were
part of routine investigations in patients who had been referred
for investigation of DH, and no additional tests were carried
out. Information on the methodology used to carry out the
drug IDT was collected from databases of 11 departments
in Europe with special interest in DH. The following data
were recorded: age and gender of the patients, the method
for filling the syringe, the injected volume of saline and
amoxicillin (AX), the injection site, and the diameter of Wi
and 20min post-injection. For AX (20 mg/ml), the parenteral
AX powder (the manufacturer may vary depending on the
center and dispensed by local hospital pharmacy) was dissolved
in sterile isotonic saline and used within 2 h of the IDT as
recommended (9).
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Questionnaires on the Methods for Doing
IDT
A questionnaire was sent by email to all the members of
the ENDA group. The main questions aimed at highlighting
differences in the local practice between centers, and the returns
are summarized in Table 1.
Evaluating Injection Volume Obtained by
Using Different Syringe Sizes and
Syringe-Filling Methods
Two methods, used in participating centers, to fill a syringe
with 0.02ml normal saline (NS) were evaluated. In Nancy,
three nurses specialized in drug allergy workup drew up exactly
0.02ml into a 1-ml syringe using a 25-G needle, which was then
emptied into a small vial (Method 1). Another nurse filled a
syringe with 0.05–0.07ml saline, then expelled the excess fluid
and air bubbles to obtain exactly 0.02ml, which was similarly
emptied into a vial (Method 2). The two procedures were
repeated 10 consecutive times. The weight of the NS collected
by both methods was determined using a precision scale (KERN
EW/EG version 2.4 11/2006) and then converted into milliliters.
Method 2 was also carried out in Copenhagen using a 1-ml
syringe as in Nancy, and a 0.5-ml syringe and a 27-G needle in
both instances.
Comparing Non-standardized Methods
With Injection of a Standardized Volume
The first part of the study was done in order to determine
if adhering to previously published international guidelines
minimizes intercenter variability in performing drug IDT; each
participating center performed IDT using its local IDT protocol
with NS and AX (20 mg/ml) test solutions. In the second part of
the study, the ENDA method, injecting a fixed volume (0.02ml)
of AX or NS, was carried out on additional new patients. We
also analyzed if the injection site, the syringe size, and the needle
gauge influenced the size of Wi.
The injection sites used for saline or AX IDT were the lateral
aspect of the upper arm (UA) and/or the flexor aspect of the
forearm (FA), and, in a limited number of patients, the back
(B). All centers used 25- to 27-G needles except one, which used
FIGURE 1 | Tuberculin syringe with a 25-G needle and a flat-end plunger
drawn up with 0.02-ml solution.
TABLE 2 | Results of Questionnaire Survey of Drug Intradermal Test (IDT) methods used in 20 European allergy centers.
Questions Answers
Number of IDT done per year 30–6,000 IDT
Do you use dissolved and filtered drug solution for IDT? Yes: 5/20 (crushed pills or other non-injectable forms of the drugs, diluted in saline then filtered)
No: 15/20
Which solvent do you use? Saline or phenolated saline: 16/20
Sterile distilled water or the solvent recommended as diluent for the infusion: 4/20










Measurement of the Wi Yes: 15/20
No: 5/20
What are your criteria for a positive immediate reading? The existence of a given diameter of W20: 4 centers (3–5mm depending on the centers)
The existence of a given diameter of erythema at 20min (E20) 3mm ≥: 6mm depending on the centers
(2 centers also consider the W20).
W20 ≥ Wi + 3 mm: 6 centers
Wi, mean diameter of the wheal (bleb or papule) immediately after ID injection.
W20, mean diameter of the wheal or the wheal developed at 20 min.
E20, mean diameter of the erythema developed at 20 min.
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30-G needles. The injection sites were inspected just after the
injection, with the measurement of the Wi and at 20min post-
injection for wheal (W20) and erythema (E20), respectively, and
their diameter was measured as recommended (2–5).
Analysis of Wi When Standardized IDT Is
Performed by Individual Tester Injecting
0.02 and 0.03ml Saline, Respectively
As the preliminary results showed that the test volumes injected
varied among allergy centers from 0.02 to 0.05ml, it was decided
to compare the most used volume of 0.03ml with the proposed
lower volume of 0.02ml NS. This was carried out by trained
operators using the standardized IDT method on volunteer
subjects in six centers.
The results obtained, the Wi obtained using the local and
the standardized IDT methods on different injection sites and
volume injected, were subject to chi-square and Kruskal–Wallis
tests and non-parametric data by Wilcoxon test. The differences
in wheal sizes were considered statistically significant if the p-
value was≤0.05. The statistical analysis was performed using SAS
software, version 9.2.
RESULTS
Questionnaires on the Methods for Doing
IDT
All centers answered that they followed the ESCD and/or EAACI
guidelines (2, 3), but no two centers carried out and interpreted
the IDT in the same way (Table 2). Even if the two European
guidelines recommended injecting a given volume (between 0.02
and 0.05ml) (2, 3), 12/20 centers did not use a fixed volume but
injected a volume to produce the targeted Wi diameter.
In addition to the answers summarized in Table 2, the centers
may differ on the syringe size and the gauge of the needle
used, on the way syringes are filled with the test solution, and
in the training for IDT. Some centers also used crushed pills,
diluted in saline then filtered, for performing IDT, which was not
recommended by any previous guidelines.
Evaluating Injection Volume Obtained by
Using Different Syringe Size and
Syringe-Filling Method
Drawing up a larger volume and expelling excess solution to the
required volume gave more reproducible result (mean 0.024ml,
SD = 0.002). This method of syringe filling was adopted into the
standardized IDT method (Figure 1). The needle gauge did not
appear to affect the injection volume obtained as shown by the
results acquired in Copenhagen and Nancy. Copenhagen (27-G
needle and 1-ml syringe) mean volume= 0.027ml (range 0.019–
0.037), SD = 0.0.0037. Nancy (25-G needle and 1-ml syringe)
mean volume = 0.027ml (range 0.012–0.037), SD = 0.0035.
When a 0.5-ml syringe instead of a 1-ml syringe was used to
draw up the solution, the mean volume was less and the standard
deviation lower, 0.023ml (range 0.017–0.027), SD= 0.0019.
Comparing Non-standardized Methods
With Injection of a Standardized Volume
Seven centers performed local non-standardized NS IDT with
injection volumes that ranged from 0.02 to 0.05ml and also with
a fixed volume of 0.03ml (Table 3). Local center IDT methods of
skin testing were based on previously published guidelines (2, 3).
There were large intercenter and interindividual variations in
the Wi when local IDT methods were compared. This is likely to
be due to the different ways the injection volume was measured
and the injection technique. There was a statistically significant
difference in the mean Wi diameter across centers even when a
fixed volume of 0.03-ml injection was used for IDT (p < 0.0001).
The overall median Wi was 5mm (n = 318) with a range of 2–
11mm, variation in meanWi of 3–8mm, and interquartile range
of 4–5 mm.
Investigation of Whether Standardized IDT
Method Reduces Intercenter Variability
During an ENDA meeting, syringe filling, differences in the
injection needle gauge, injection technique, and reading of the
skin reaction were evaluated.
Needles of 25–30G did not affect the Wi produced. However,
the volume of the syringe used affected the actual volume
drawn up into the syringe, probably due to the dead volume
of the syringe. In addition, a 0.5-ml syringe has wider
spacing between markings, which enables a more accurate
measurement of volume of the test solution. Unfortunately,
the 0.5-ml syringe is not available throughout Europe. We
also consider the variability due to syringe size to be limited.
For the standardized method, we, therefore, advised that
either 0.5- or 1-ml syringes can be used for IDT, subject to
local availability.
To help decide on the test volume to be used in
the study, NS IDT was performed on the skin of the
coauthors of this study. It was noted that larger injection
volumes (>0.02ml) tended to produce very big wheals. A
standardized IDT method with a description of each step,
using 0.02-ml injection, was proposed and agreed by the study
group (Table 4).
Eight centers performed IDT using 0.02-ml saline, and six of
these, in addition, performed IDT with 0.02-ml AX (20 mg/ml).
IDT performed with standardized method syringe filling
(Figure 1) and 0.02-ml saline on 1,096 patients (Table 5)
showed that a significant difference in the Wi persisted
between centers (p < 0.0001). However, differences in
the mean and median diameters between centers were
reduced, with variation in the mean Wi (4.5–5.4mm)
in the range 2–10mm, with a median diameter of 5mm
(IQR 5–5mm).
IDT with standardized syringe filling with 0.02-ml AX
performed on 240 patients gave a mean Wi diameter of 5.2mm
and a median Wi of 5mm (range 2–9mm, IQR 4.5–5mm). The
difference inWi between centers remained statistically significant
(p < 0.0001) (Table 5).
There was no correlation of wheal size with age or sex with
either local methods or standardized IDT.
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TABLE 3 | Median injection wheal (Wi) diameter for intradermal tests with saline using non-standardized individual protocols, demonstrating large inter-center variations.
Center Porto Vilnius Ankara Paris (Necker) Firenze Nancy Munich Total
Mean age (yrs.) 8 47 43 9 45 55 32 42
Site
UA (n) 15 9 24 24 72
FA (n) 6 32 11 99 22 24 194
B (n) 28 24 52
Injected volume
0.02ml (n) 3 36 39
0.03ml (n) 6 22 48 9 99 46 36 266
0.04–0.05ml (n) 10 3 13
Total (n) 6 32 54 9 99 46 72 318
Median Wi diameter (R)
mm by center





UA, Upper Arm; FA, Forearm; B, Back; n, number of tests; R, range minimal and maximal; IQR, interquartile range.
**The variables were subject to a chi-squared test for the qualitative variables, a Kruskal-Wallis test for the quantitative variables.
TABLE 4 | Summary of proposed ENDA protocol for performing and reading drug intradermal test.
1. IDT must be performed, following negative prick tests, using pharmaceutical grade human drugs in injectable form. IDT is contraindicated in severe cutaneous
adverse drug reactions
2. Syringe size and needle gauge:
• Tuberculin syringe of preferably 0.5ml or if not available, 1-ml volume
• Needle gauge of 25, 27, or 30G
• Same fixed or new needle can be used for test IDT
3. Injection technique:
- Adopt sterile techniques.
- Fill syringe with test solution; change the needle if not fixed. Tap the barrel of the syringe to make the air bubble rise to the needle end of the syringe. Expel air bubble
and excess volume pushing the plunger to the 0.02-ml mark on the barrel (Figure 1). A syringe with a flat end plunger is better than one with a tapered end to help
measure the volume of the test solution drawn into the syringe.
- With the bevel of the needle facing upward, pierce skin tangentially in the upper dermis (at about 10◦ angle to the skin surface).
- Then slowly inject the measured volume intradermally.
4. Control:
- After intradermal injection of 0.02ml of saline or test solution at recommended concentration, an injection wheal measuring 4.5- to 5.5-mm diameter should form.
- If no clear wheal forms, repeat injection.
5. Record all injected solutions, batch number, and map of injection sites. Draw around and/or measure the diameter of the immediate injection wheal (Wi). If you
surround the wheal with ink, always measure the inner diameter.
6. Read the IDT after 20min. Measure wheal (W20) and surrounding erythema (E20).
7. If the wheal is not round, measure the length (L), then the width (w) taken perpendicularly, in the middle of the axis length Wi = (L+w)/2.
8. In patient records and publications, IDT results must be recorded as follows: Wi, W20, and E20.
9. At 20min, the IDT is considered positive only if there is a wheal, W20 ≥ Wi + 3mm and surrounding erythema, E20.
10. For delayed reactions read at 24, 48 h, or later (please specify the time interval). IDTs are considered positive when there is an erythematous induration or swelling
at the injection site.
Analysis of Wi When Standardized IDT Is
Performed by Individual Tester Injecting
0.02- and 0.03-ml Saline, Respectively
The Wi obtained by an individual tester injecting 0.02- and 0.03-
ml NS, respectively, using the standardized IDT was compared in
six different centers (Table 6).With 0.02-ml NS injection volume,
the Wi mean diameter was 5.1mm (range 3–8mm) and median
= 5mm (IQR 4.5–5mm). When 0.03-ml NS was injected, the
mean Wi was 6.2mm (range 3–8mm) and median = 6mm
(IQR 5.5–6mm) (Table 6).
Standardization of IDT produced larger Wi. For the 0.03-ml
injection volume, the mean Wi was 6mm (Table 6) compared
to 5mm before standardization (Table 3). However, the smaller
injection volume of 0.02ml produced smaller Wi (5mm)
(Table 6).
Injection Site Does Not Affect Wi Readings
The Wi diameter was not affected by the injection site when the
standardized IDT method was used. NS IDT was performed on
two or more injection sites (UA, FA, B) in three centers (Ankara,
Nancy, and Munich). There was no significant difference in
the Wi diameter obtained in the different injection sites (p >
0.05) (Table 3). In addition, the Wi diameter obtained using
the standardized IDT with NS and AX at the recommended
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TABLE 5 | Diameter of IDT injection wheal (Wi) after injecting 0.02ml saline and amoxicillin (20 mg/ml) using standardized method for drug intradermal tests.
Porto Vilnius Ankara Firenze Nancy Malaga Graz Groningen Total
Saline number tested 26 87 78 118 734 6 24 23 1,096
Age 10 51 48 46 59 28 28 44 43
Site
UA 0 0 0 0 409 0 8 0 417
FA 26 87 78 118 133 6 8 23 479
Back 192 8 200
Median Wi diameter (R)
mm
5 (4–6) 5 (3–10) 5 (4–6) 5 (3–6) 5 (2–7) 5 (4–6) 5.4 (4–7) 4.5 (3–6) Wi diameter
Median 5mm
Range (2–10)





3 23 0 86 88 17 0 23 240
Age 5 51 45 53 35 44 48
Site
UA 0 0 0 0 88 0 0 0 88
FA 3 23 0 86 0 17 0 23 152
Median Wi diameter (R)
mm by center
5 (5–6) 6 (4–9) 5 (3–6) 5 (2–7) 6.4 (4–7) 5 (4–7) Wi diameter
Median 5mm
Range (2–9)
Q1 = 4.5, Q3 = 5,
IQR = 0.5,
**p < 0.0001
R, range minimal and maximal; IQR, interquanrile range; Wi, injection wheal; UA, Upper Arm; FA, Forearm; B, Back. **The variables were subject to a chi-squared test for the qualitative
variables and a Kruskal-Wallis test for the quantitative variables.
TABLE 6 | Comparison of diameter of IDT injection wheal (Wi) after injection of saline (0.02ml or 0.03ml) by trained operators using the standardized method and syringe
size used.
Groningen Firenze Porto Nancy Malaga Munich Total
Number of volunteers 23 11 10 15 10 8 77
Mean age 44 44 34 30 48 30 30
Site (p = 0.4735)
UA (N) 0 0 0 30 0 0 30
FA (N) 46 22 20 0 20 16 124
Wi diameter (mm) with injection volume (ml)
0.02ml 5 (3–6) 5 (4–7) 5 (4–6) 5 (5–6) 6 (5–7) 5 (5–8) 5 (3–8)
0.03ml 6 (3–6) 6 (5–8) 6 (6–7) 6 (6–6) 7 (6–8) 7 (6–7) 6 (3–8)
Syringe size (ml)
0.5ml (n) 46 0 20 0 0 0 66
1ml (n) 0 22 0 30 20 16 88
N, number of test; M, median; R, range; SD, standard deviation; UA, Upper arm; FA, Forearm; IQR, interquartile range; No difference of Wi according to the site of injection (p = 0.4735).
concentrations (8–10) performed on the UA, FA, and B was not
significantly different and suggested that variation of the test
results between centers was independent of the injection site and
the drug used. Differences in Wi in different sites in the same
individual patients were not compared.
DISCUSSION
IDTs are essential for the diagnosis of DH. This study
demonstrates significant differences in the IDT methods used,
in the volume injected, and in the Wi diameter obtained by the
study centers. It shows that standardization of the IDT procedure
and injection volume produced improved, reproducible, and
more comparable skin test results. Tester training had a positive
influence on precision and reduced variability. The identification
of several causes of variability in the performance of IDT enabled
an IDT standardized method to be proposed (Table 4). The
adoption of the proposed method and training should lead to
more reproducible and comparable results between centers and
clinical studies.
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In spite of the many guidelines published, our questionnaire
survey of 20 allergy centers in ENDA showed that the majority
did not follow published guideline recommendations. Indeed,
most of the centers (12/20) did not inject a fixed volume as
recommended by all guidelines (2–6), but injected a volume
to achieve the target Wi. Using a fixed volume of an IDT
drug solution of known concentration means injecting a known
and fixed quantity of the tested drug. Drug IDT could induce
immediate or delayed flare reactions in addition to the wheal
(11, 12). The incidence of these flares may depend on themethod,
the concentrations, and the volume injected. Three flares were
observed among 30 patients with IDTs for cutaneous adverse
drug reactions (11). The incidence of systemic reactions in
patients with positive skin tests to penicillin varies from 0.7 to
9.4% (12, 13). Even with a fixed injection volume, the diameter
of Wi could be affected by the age of the individual and the
degree of skin atrophy. Injecting a fixed test volume would allow
more robust comparison of IDT results between individuals and
centers. As illustrated in Table 1, the five guidelines vary in
the volume of drug injected, the target Wi diameter, the time
before reading the immediate skin reaction, the criteria for an
immediate and delayed positive test reading, and the site for
performing IDT. The differences in the Wi diameter following
injection of test volumes used in the guidelines and in our
standardized method are stark.
With the ENDA IDT standardized method, the 0.02-ml
injection volume produced a mean Wi of 5.1mm (range 3–
8mm), whereas 0.03ml produces a mean Wi diameter of
6.2mm (3–8mm), median = 6mm. With the ESCD guidelines
showing that injecting 0.04ml results in raising a Wi of 4–
6mm (2), the EAACI guidelines show that injecting 0.02–
0.05ml produced a Wi of 3mm (3), and the SFAR guidelines
show that injecting 0.02–0.05ml caused a Wi ≤4mm (5).
Such differences make the comparison of IDTs performed
following different guidelines of doubtful value. The BSACI
guideline uses a fixed volume of 0.03ml. The resulting wheal,
a median Wi of 6mm, is similar to that obtained by the
ENDA standardized method. However, there is a difference
in the time when the immediate test reading is taken, 20–
30min with the BSACI guideline and 20min with the ENDA
standardized method.
Macy et al. (6), in their IDT protocol, used 0.02ml and took
the reading of the immediate reaction 15min after the injection,
which was considered positive when the wheal is ≥5mm. In
a recent paper, the similarities and differences between Europe
and North America in the approach to the diagnosis of DH
reactions have been highlighted (14). However, the method for
doing and reading IDT, which we have shown to be different
among ENDA allergy centers, is not in the list of differences
between the two continents.
With the standardized IDT method, the 0.02-ml injection
volume produced a mean Wi of 5.1mm, whereas 0.03ml and
above produced a Wi diameter of 6.2mm (3–8mm). Due to the
small risk of sensitization and anaphylaxis induced by IDT (9), it
is considered good practice to inject a small as possible volume
of potential drug allergen that will produce a test wheal that
enables accurate reading of the diameter. That is why we have
recommended that 0.02ml of non-irritating test allergen solution
should be used for IDT.
Variability could also be caused by differences in measuring
wheal sizes and differences in the depth of injection. The
somewhat surprising but interesting finding that the injection
site did not significantly affect Wi needs further evaluation. It
appears that IDT is amore complicated and variable method than
previously acknowledged and that detailed recommendations
and training are needed for method consistency and reproducible
results and interpretation. Intertester variability could be reduced
by having designated trained members of staff to perform
IDT (15).
We hope that these highly detailed ENDA guideline for
performing IDT will help to standardize the IDT method.
We envisage that further studies will be necessary using this
standardized method to determine if Wi could be affected by the
age of the patient, the test site, and skin atrophy. It would also
be interesting to determine the negative predictive value of IDT
in using different criteria for their positivity W20 ≥ Wi+ 3mm,
W20 ≥Wi× 2 or W20≥ a fixed diameter of 10 or 5 mm.
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